Stocks Hitting 52-Week Lows

shares touched a new 52-week low of $10.78 after providing an update on three current ongoing clinical programs in patients with NSCLC and other solid tumors. Jefferies downgraded Mirati Therapeutics from Buy to Hold and lowered the price target from $27.00 to $17.00.

shares fell 6.21 percent to touch a new 52-week low of $1.66. Great Basin Scientific shares have dropped 99.98 percent over the past 52 weeks, while the S&P 500 index has gained 0.95 percent in the same period.

shares declined 64.75 percent to reach a new 52-week low of $2.25 after the company reports interim data from Wolverine Phase 2 trial of PNT2258 in diffuse large B-cell lymphoma (DLBCL). The company discontinued the development of DLBCL.

shares dropped 1.01 percent to touch a new 52-week low of $16.66. SeaWorld Entertainment shares have declined 17.62 percent over the past 52 weeks, while the S&P 500 index has gained 0.95 percent in the same period.